Cassels_2005_Drug.Discov.Today_10_1657

Reference

Title : From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research - Cassels_2005_Drug.Discov.Today_10_1657
Author(s) : Cassels BK , Bermudez I , Dajas F , Abin-Carriquiry JA , Wonnacott S
Ref : Drug Discov Today , 10 :1657 , 2005
Abstract :

S-Nicotine, the principal psychoactive constituent of Nicotiana tabacum, underpins addiction to tobacco smoking. Although tobacco consumption is a leading cause of death worldwide, nicotine itself is also proposed to have potential therapeutic benefits for a diverse range of conditions. Nicotine interacts with its cognate receptors in the central nervous system to exert a predominantly modulatory influence, making neuronal nicotinic receptors attractive therapeutic targets. Here, we focus on three natural products as lead compounds for drug discovery programs, nicotine, epibatidine and cytisine, and consider the aims and limitations that shape these drug discovery endeavors.

PubMedSearch : Cassels_2005_Drug.Discov.Today_10_1657
PubMedID: 16376826

Related information

Citations formats

Cassels BK, Bermudez I, Dajas F, Abin-Carriquiry JA, Wonnacott S (2005)
From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research
Drug Discov Today 10 :1657

Cassels BK, Bermudez I, Dajas F, Abin-Carriquiry JA, Wonnacott S (2005)
Drug Discov Today 10 :1657